Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
9.32
USD
+4.60%
+5.79%
-26.90%
This article is reserved for members
Not a member ?
Free registration
Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M
May. 01
MT
Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024
May. 01
Pulmonx Corporation Provides Revenue Guidance for the Full Year 2024
May. 01
CI
Pulmonx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 01
CI
Pulmonx Appoints Mehul Joshi as Chief Financial Officer
Apr. 02
MT
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024
Apr. 02
CI
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial
Feb. 26
CI
North American Morning Briefing : Traders Await -2-
Feb. 26
DJ
Pulmonx Shares Fall After Wells Fargo Downgrade
Feb. 23
MT
Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16
Feb. 23
MT
Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating
Feb. 22
MT
Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating
Feb. 22
MT
Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating
Feb. 22
MT
Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating
Feb. 22
MT
Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating
Feb. 22
MT
Transcript : Pulmonx Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Feb. 21
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M
Feb. 21
MT
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024
Feb. 21
CI
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 21
CI
Pulmonx Corporation Announces Chief Executive Officer Changes, Effective March 15, 2024
Feb. 21
CI
Pulmonx Corporation Announces Executive Changes, Effective March 15, 2024
Feb. 21
CI
Pulmonx Insider Sold Shares Worth $292,000, According to a Recent SEC Filing
Feb. 20
MT
Transcript : Pulmonx Corporation, Q3 2023 Earnings Call, Oct 30, 2023
23-10-30
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q3 Revenue $17.7M, vs. Street Est of $16.7M
23-10-30
MT
Pulmonx Corporation Provides Earnings Guidance for 2023
23-10-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
More about the company
Last Close Price
9.32
USD
Average target price
15.4
USD
Spread / Average Target
+65.24%
Consensus
1st Jan change
Capi.
-26.90% 362M +73.63% 12.42B -18.62% 7.94B -0.90% 6.17B +14.66% 5.5B +39.93% 5.01B -16.38% 4.88B -16.42% 4.2B -27.62% 2.73B +40.99% 2.27B
Medical Equipment
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**